Chronic Heart Failure

1. Anatomy & Physiology

1.1 Gross Cardiac Anatomy

The human heart is a four-chambered muscular pump located within the middle mediastinum, oriented obliquely with its apex directed anteriorly, inferiorly, and to the left. Understanding the macroscopic architecture is foundational to localizing heart failure phenotypes [1].

1.1.1 Atrial Architecture

• Right Atrium (RA): Receives deoxygenated blood from the superior vena cava (SVC), inferior vena cava (IVC), and coronary sinus. The interior features the crista terminalis, separating the smooth-walled posterior part from the anterior part containing pectinate muscles.
• Left Atrium (LA): Receives oxygenated blood from the four pulmonary veins. It is more posterior than the RA. The left atrial appendage (LAA) is a significant site for thrombus formation, particularly in the context of heart failure-associated atrial fibrillation.

1.1.2 Ventricular Architecture

• Right Ventricle (RV): A crescent-shaped chamber in cross-section, the RV is a low-pressure system designed for high compliance. It contains the trabeculae carneae, the moderator band (septomarginal trabecula), and the infundibulum (conus arteriosus) leading to the pulmonary valve.
• Left Ventricle (LV): The primary high-pressure pump, featuring a conical shape and walls significantly thicker (8–12 mm) than the RV (3–5 mm). The LV must overcome systemic vascular resistance (SVR), making its geometry critical to the pathophysiology of remodeling [2].

1.1.3 Valvular Apparatus and Fibrous Skeleton

The four valves ensure unidirectional flow:

1. Atrioventricular (AV) Valves: Tricuspid (Right) and Mitral (Left). These are connected via chordae tendineae to papillary muscles, preventing eversion during systole.
2. Semilunar Valves: Pulmonary and Aortic. These consist of three cusps and lack chordae. The Cardiac Skeleton is a dense connective tissue structure that provides electrical insulation between the atria and ventricles, forcing the impulse through the AV node, and provides structural support for the valves.

1.2 Microscopic Structure: The Cardiomyocyte

The cardiomyocyte is the specialized unit of cardiac contraction. Unlike skeletal muscle, cardiac myocytes are branched, shorter, and connected via complex junctions [3].

1.2.1 Intercalated Discs

These are specialized cell-cell junctions that allow the heart to function as a functional syncytium:

• Fascia Adherens: Anchors actin filaments and transmits contractile force.
• Desmosomes: Provides mechanical stability during high-stress contraction.
• Gap Junctions: Facilitates rapid ion transfer and electrical coupling, essential for synchronized contraction.

1.2.2 The Sarcomere: The Molecular Engine

The sarcomere is the basic functional unit of the myofibril, delimited by Z-discs.

• Thick Filaments: Composed primarily of Myosin II. The myosin heads contain ATPase activity and bind to actin.
• Thin Filaments: Composed of Actin, Tropomyosin, and the Troponin complex (TnT, TnI, TnC).
  • TnC: Binds calcium ions (Ca2+).
  • TnI: Inhibitory subunit that prevents myosin binding in the absence of calcium.
  • TnT: Binds the troponin complex to tropomyosin.
• Titin: A giant elastic protein that spans from the Z-disc to the M-line. It acts as a molecular spring, contributing to passive stiffness and the Frank-Starling mechanism [4].

1.3 Cardiac Physiology and the Cardiac Cycle

The cardiac cycle is a highly coordinated sequence of electrical and mechanical events divided into systole (contraction) and diastole (relaxation).

1.3.1 Phases of the Cardiac Cycle (Wiggers Context)

1. Atrial Systole: Follows the P-wave; provides the "atrial kick" (20-30% of LV filling).
2. Isovolumetric Contraction: LV pressure rises rapidly above LA pressure (closing the mitral valve, $S_1$) but remains below aortic pressure. Volume is constant.
3. Ventricular Ejection: LV pressure exceeds aortic pressure, opening the aortic valve.
4. Isovolumetric Relaxation: LV pressure falls below aortic pressure (closing the aortic valve, $S_2$). Volume is constant.
5. Ventricular Filling: LV pressure falls below LA pressure, opening the mitral valve. Includes rapid filling, diastasis, and atrial contraction.

1.3.2 Hemodynamics and Starling's Law

Cardiac Output (CO): CO = Stroke Volume (SV) × Heart Rate (HR).

• Stroke Volume: Influenced by Preload, Afterload, and Contractility. Frank-Starling Law: States that the force of ventricular contraction is proportional to the initial length of the muscle fibers (End-Diastolic Volume). This is mediated by increased Ca2+ sensitivity and optimized actin-myosin overlap [5]. Laplace’s Law: σ = (P × r) / 2h, where σ is wall stress, P is transmural pressure, r is radius, and h is wall thickness. In heart failure, ventricular dilation (increased r) increases wall stress, which drives further remodeling and oxygen demand.

1.3.3 Excitation-Contraction Coupling (ECC)

The process begins with an action potential triggering the opening of L-type Calcium Channels (I_CaL). The resulting small influx of Ca2+ triggers a much larger release of Ca2+ from the Sarcoplasmic Reticulum (SR) via Ryanodine Receptors (RyR2)—a process known as Calcium-Induced Calcium Release (CICR). Relaxation occurs when Ca2+ is pumped back into the SR by the SERCA2a pump (regulated by phospholamban) or extruded via the Na+/Ca2+ exchanger (NCX).

---

2. Epidemiology

2.1 Global Burden and Prevalence

Heart failure is a global pandemic affecting approximately 64.3 million people worldwide [6]. Its prevalence is increasing due to an aging global population and improved survival following acute myocardial infarction.

2.1.1 Prevalence by Region and Age

• Global Prevalence: ~1–2% of the adult population.
• Age-Stratification: Prevalence rises sharply with age, from less than 1% in those under 55 to > 10% in those over 75 years of age.
• Economic Impact: In high-income countries, HF accounts for 1–2% of the total healthcare budget, primarily driven by hospitalizations [7].

2.1.2 HFrEF vs. HFpEF Trends

• HFpEF (LVEF ≥50%): Now accounts for approximately 50% of all HF cases. Its incidence is rising faster than HFrEF, particularly among elderly women and those with metabolic syndrome.
• HFrEF (LVEF ≤40%): Incidence is stabilizing or slightly declining in some regions due to better management of coronary artery disease (CAD) and hypertension.

2.2 Risk Factors and Etiology

The 2024–2025 landscape highlights the multi-morbid nature of heart failure.

2.3 Mortality and Morbidity

Despite the advent of Guideline-Directed Medical Therapy (GDMT), HF remains as lethal as many common cancers.

• Survival Rates: The 1-year mortality rate is ~15-20%, while the 5-year mortality rate remains near 50% [8].
• Readmission: HF is the leading cause of hospitalization in adults over 65. Approximately 20-25% of patients are readmitted within 30 days of discharge.

---

3. Pathophysiology

3.1 The "Index Event" and Compensatory Logic

Heart failure typically begins with an index event (e.g., myocardial infarction, chronic hypertension, viral myocarditis) that impairs the heart's ability to pump or fill. To maintain cardiac output and systemic perfusion, the body activates a suite of compensatory mechanisms. While beneficial in the short term, chronic activation of these pathways is maladaptive and drives the progression of the disease [9].

3.2 Neurohormonal Activation

The neurohormonal hypothesis is the cornerstone of modern HF management.

3.2.1 The Sympathetic Nervous System (SNS)

Reduced cardiac output triggers baroreceptor unloading, leading to increased sympathetic outflow:

• Direct Effects: Increases heart rate (chronotropy) and contractility (inotropy) to maintain CO.
• Maladaptive Sequelae: Chronic exposure to high Norepinephrine levels leads to: Beta-receptor Downregulation: Reduced density and sensitivity of β1 receptors.
  • Myocyte Toxicity: Direct catecholamine-induced apoptosis and necrosis.
  • Arrhythmogenesis: Increased triggered activity and reentry.

3.2.2 The Renin-Angiotensin-Aldosterone System (RAAS)

Reduced renal perfusion and SNS stimulation trigger the release of Renin from the juxtaglomerular apparatus.

1. Angiotensin II: A potent vasoconstrictor that increases afterload. It also binds to AT1 receptors on myocytes, stimulating hypertrophy, and on fibroblasts, stimulating collagen synthesis.
2. Aldosterone: Released from the adrenal cortex. It promotes Na+ and water retention (increasing preload) and directly promotes interstitial fibrosis in the myocardium and vasculature [10].

3.2.3 The Natriuretic Peptide System: The "Counter-Regulatory" Pathway

In response to myocardial stretch, the heart secretes:

• ANP (Atrial Natriuretic Peptide): From the atria.
• BNP (B-type Natriuretic Peptide): Primarily from the ventricles. These peptides promote vasodilation, natriuresis (sodium excretion), and diuresis, and inhibit the RAAS and SNS. In chronic HF, this system is overwhelmed, and the peptides are rapidly degraded by Neprilysin (neutral endopeptidase), providing the rationale for ARNI therapy.

3.3 Cardiac Remodeling

Remodeling refers to the changes in size, shape, structure, and function of the heart.

3.3.1 Cellular Alterations

• Hypertrophy: Cardiomyocytes increase in size (not number).
  • Concentric: In response to pressure overload (e.g., HTN); sarcomeres added in parallel.
  • Eccentric: In response to volume overload (e.g., valve regurgitation); sarcomeres added in series, leading to chamber dilation.
• Mitochondrial Dysfunction: Shift from fatty acid oxidation to glucose utilization (the "fetal gene program"), resulting in ATP deficiency.
• Excitation-Contraction Uncoupling: Altered calcium handling (reduced SERCA2a activity) leads to reduced contractility and impaired relaxation.

3.3.2 Extracellular Matrix (ECM) and Fibrosis

Heart failure is characterized by the transformation of fibroblasts into myofibroblasts. This leads to:

• Interstitial Fibrosis: Collagen deposition between cells, increasing myocardial stiffness (predominant in HFpEF).
• Replacement Fibrosis: Scar tissue following myocyte death (predominant in HFrEF post-MI).

3.4 Inflammation and Oxidative Stress

Chronic HF is a state of sterile systemic inflammation.

• Cytokines: Elevated levels of TNF-α, IL-1β, and IL-6 correlate with disease severity. These cytokines suppress myocyte contractility and promote cachexia.
• Oxidative Stress: Overproduction of Reactive Oxygen Species (ROS) damages DNA, proteins, and lipids, further impairing mitochondrial function and accelerating apoptosis [11].

---

3.5 References (Chunk 1)

1. Anderson RH, et al. Anatomy of the Heart. In: Hurst's The Heart, 15th Ed. 2024.
2. Katz AM. Physiology of the Heart. 6th Ed. Lippincott Williams & Wilkins. 2021.
3. Sequeira V, van der Velden J. Historical perspective on heart function: the cardiac sarcomere. Pflugers Arch. 2017;469(3-4):413-425.
4. Granzier HL, Labeit S. The Giant Protein Titin. Circ Res. 2004;94(3):284-295.
5. Shiels HA, White E. The Frank-Starling Mechanism in Mammalian Heart. J Exp Biol. 2008;211(13):2005-2013.
6. GBD 2021 Heart Failure Collaborators. Global, regional, and national burden of heart failure, 1990–2021. Lancet. 2024.
7. Savarese G, et al. Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology. Cardiovasc Res. 2023;118(17):3272-3287.
8. Tsao CW, et al. Heart Disease and Stroke Statistics—2024 Update. Circulation. 2024;149(3):e347-e913.
9. Mann DL. Mechanisms and Models in Heart Failure. Circulation. 1999;100(9):999-1008.
10. Weber KT. Aldosterone in Congestive Heart Failure. N Engl J Med. 2001;345(23):1689-1697.
11. Murphy SP, et al. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(11):1324-1340.

4. Clinical Presentation

The clinical presentation of chronic heart failure (CHF) is characterized by a constellation of symptoms and signs resulting from inadequate systemic perfusion and/or elevated intracardiac filling pressures. In the early stages, symptoms may only manifest during physical exertion, but as the disease progresses, they occur at rest, profoundly impacting quality of life [12].

4.1 Clinical History: Cardinal Symptoms

The history should focus on identifying the classic triad of dyspnoea, fatigue, and fluid retention.

• Dyspnoea on Exertion (DOE): Typically the earliest and most common symptom. It is graded by the level of activity required to induce it.
• Orthopnoea: Shortness of breath when lying flat, caused by the redistribution of fluid from the lower extremities and splanchnic circulation to the central venous system, increasing pulmonary capillary pressure. It is often quantified by the number of pillows the patient uses to sleep.
• Paroxysmal Nocturnal Dyspnoea (PND): A highly specific symptom where the patient awakens gasping for air 1–3 hours after falling asleep. Unlike orthopnoea, which is relieved immediately by sitting up, PND often takes 15–30 minutes to resolve.
• Exercise Intolerance and Fatigue: Resulting from reduced skeletal muscle perfusion and abnormalities in skeletal muscle metabolism (the "muscle hypothesis" of heart failure) [13].
• Bendopnoea: Shortness of breath when leaning forward (e.g., to tie shoelaces), a relatively recently described sign indicative of high filling pressures.
• Other Symptoms: Nocturia (early sign), abdominal bloating/anorexia (due to hepatic/gut congestion), and a chronic non-productive cough (often worse when supine).

4.2 Physical Examination: Key Signs

A systematic examination is essential to assess the volume status and identify the underlying phenotype.

4.2.1 General Appearance and Vital Signs

• Tachycardia: A compensatory response to reduced stroke volume.
• Pulse Pressure: Narrow pulse pressure (e.g., less than 25 mmHg) suggests a low stroke volume.
• Pulsus Alternans: A beat-to-beat variation in pulse volume in the setting of a regular rhythm; pathognomonic for severe LV systolic dysfunction.
• Cheyne-Stokes Respiration: A pattern of periodic breathing (crescendo-decrescendo hyperpnoea followed by apnoea), often seen in advanced HF.

4.2.2 Congestive (Wet) Signs

• Jugular Venous Pressure (JVP): Elevated JVP is the most reliable physical sign of fluid overload and right-sided filling pressures. A persistent elevation > 8 cm H2O is associated with poor prognosis [14].
• Hepatojugular Reflux (HJR): Sustained elevation of JVP (> 3 cm) during 10–15 seconds of firm pressure on the mid-abdomen.
• Pulmonary Crackles (Rales): Typically fine, inspiratory, and bibasilar. Note: Crackles may be absent in chronic HF due to increased lymphatic drainage.
• Peripheral Oedema: Usually symmetrical, pitting, and dependent (ankles/sacrum).
• Pleural Effusions: More common on the right side or bilateral.
• Ascites and Hepatomegaly: Signs of severe right-sided congestion.

4.2.3 Cardiac Signs

• Displaced Apex Beat: An apical impulse lateral to the mid-clavicular line or below the 5th intercostal space indicates LV dilation.
• S3 Gallop (Ventricular Gallop): A low-pitched sound in early diastole caused by rapid ventricular filling into a non-compliant or overfilled ventricle. Highly specific for HFrEF and elevated filling pressures [15].
• S4 Gallop (Atrial Gallop): Occurs in late diastole; signifies atrial contraction into a stiff ventricle (common in HFpEF and LVH).
• Murmurs: Often present due to functional mitral or tricuspid regurgitation (secondary to chamber dilation).

4.3 NYHA Functional Classification

The New York Heart Association (NYHA) system remains the standard for functional assessment.

---

5. Differential Diagnosis

Heart failure is a clinical syndrome that can be mimicked by various pulmonary, metabolic, and vascular conditions. Distinguishing HF from these mimics is critical for appropriate therapy.

5.1 Comparison of Common Mimics

---

6. Investigations

The diagnostic workup for HF aims to confirm the diagnosis, identify the phenotype (HFrEF, HFmrEF, or HFpEF), and determine the underlying cause.

6.1 First-Line Investigations (The "Screening" Phase)

These should be performed in all patients with suspected HF.

1. Electrocardiogram (ECG): A completely normal ECG has a high negative predictive value (> 90%) for HF. Common abnormalities include Q-waves (old MI), LV hypertrophy, bundle branch blocks (especially LBBB), and atrial fibrillation.
2. Natriuretic Peptides (BNP or NT-proBNP): The preferred initial diagnostic test.
   • BNP less than 100 pg/mL or NT-proBNP less than 300 pg/mL (acute) essentially rules out HF.
   • BNP less than 35 pg/mL or NT-proBNP less than 125 pg/mL (non-acute/chronic) makes HF unlikely [16].
   • Note: Values can be falsely elevated in AF, advanced age, and renal failure, and falsely low in obesity.
3. Chest X-Ray (CXR): Useful for identifying pulmonary congestion and alternative pulmonary diagnoses.
   • Findings: Cardiomegaly (CTR > 50%), Cephalization of pulmonary veins, Kerley B lines (interstitial oedema), pleural effusions.
4. Laboratory Studies: FBC, U&Es (baseline for ACEi/MRA), LFTs (congestive hepatopathy), Thyroid function (HF trigger), HbA1c, and Iron studies (ferritin/TSAT) [17].

6.2 Gold Standard: Echocardiogram

Transthoracic Echocardiography (TTE) is the most useful diagnostic tool. It provides:

• LVEF: Categorizes HF (HFrEF $\le$40%; HFmrEF 41–49%; HFpEF $\ge$50%).
• Chamber Size: LV end-diastolic and end-systolic volumes.
• Diastolic Function: E/e' ratio, LA volume index, tricuspid regurgitation (TR) velocity.
• Valvular Function: Identifies primary (e.g., AS) or secondary (e.g., MR) valvular disease.
• Wall Motion: Identifies regional wall motion abnormalities (suggesting CAD).

6.3 Advanced Imaging

• Cardiac Magnetic Resonance (CMR): The "Gold Standard" for volume and EF quantification. Its unique strength is Tissue Characterization via Late Gadolinium Enhancement (LGE), which helps differentiate between ischaemic (subendocardial) and non-ischaemic (mid-wall/epicardial) cardiomyopathies [18].
• Cardiac CT: Primarily used to rule out CAD in patients with low-to-intermediate pre-test probability.

6.4 Invasive Investigations

• Coronary Angiography: Recommended in patients with HF and angina or suspected ischaemic heart disease.
• Endomyocardial Biopsy (EMB): Rarely used; reserved for cases of rapidly progressive HF where a specific diagnosis would change management (e.g., giant cell myocarditis, amyloidosis, sarcoidosis).

---

7. Diagnostic Criteria

The diagnosis of HF requires a combination of clinical assessment and objective evidence.

7.1 ESC/AHA/HFSA Universal Definition (2021)

The universal definition requires:

1. Symptoms and/or Signs of HF.
2. Objective evidence of cardiac dysfunction (LVEF impairment, chamber enlargement, valvular disease, or diastolic dysfunction).
3. AND at least one of the following:
   • Elevated natriuretic peptide levels.
   • Objective evidence of systemic or pulmonary congestion (via imaging or haemodynamic measurement) [19].

7.2 Framingham Criteria

Historically used in clinical trials; requires 2 major or 1 major + 2 minor criteria.

---

8. Special Tests

8.1 Cardiopulmonary Exercise Testing (CPET)

CPET provides the most accurate assessment of functional capacity by measuring gas exchange during exercise.

• Peak VO2: The maximum oxygen uptake. A peak VO2 less than 12-14 mL/kg/min is a strong predictor of mortality and is used to time heart transplantation.
• VE/VCO2 Slope: Measures ventilatory efficiency. A slope > 35 indicates significant ventilatory-perfusion mismatch and poor prognosis [20].

8.2 Stress Echocardiography

Used to assess:

• Ischaemia: In patients with suspected CAD.
• Contractile Reserve: In HFrEF, the ability of the LV to increase EF with dobutamine is a positive prognostic sign and predicts recovery after revascularization.
• Diastolic Stress Test: In suspected HFpEF where resting Echo is inconclusive; an increase in E/e' with exercise suggests HFpEF.

---

9. Procedures

9.1 Right Heart Catheterization (RHC / Swan-Ganz)

RHC involves passing a balloon-tipped catheter through the right heart into the pulmonary artery.

9.1.1 Indications

RHC is not routine in chronic HF but is indicated in:

1. Evaluation for Heart Transplant or LVAD: To ensure pulmonary vascular resistance (PVR) is not prohibitively high.
2. Diagnostic Uncertainty: To differentiate between cardiogenic and non-cardiogenic dyspnoea.
3. Refractory HF: To tailor therapy in patients who are not responding to standard diuresis.
4. Assessment of Pulmonary Hypertension: To differentiate Pre-capillary vs. Post-capillary PH.

9.1.2 Key Haemodynamic Parameters

• Pulmonary Artery Wedge Pressure (PAWP): Indirect measure of LA pressure. PAWP > 15 mmHg is the hallmark of left-sided heart failure.
• Cardiac Index (CI): $CO / BSA$. Normal is 2.5–4.0 $L/min/m^2$.
• Systemic Vascular Resistance (SVR): Often elevated in HF as a compensatory mechanism.
• Pulmonary Vascular Resistance (PVR): Elevated PVR (> 3 Wood Units) indicates pulmonary vascular remodeling [21].

---

9.2 References (Chunk 2)

12. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
13. Poole DC, et al. The skeletal muscle pump: reflections on its physiological roles. J Appl Physiol. 2012;113(12):1902-1914.
14. Drazner MH, et al. Prognostic Importance of Elevated Jugular Venous Pressure and a Third Heart Sound in Patients with Heart Failure. N Engl J Med. 2001;345(8):574-581.
15. Shah SJ, et al. The S3 Gallop: Its Mechanisms and Clinical Significance. J Am Coll Cardiol. 2024 (In Press/Updated Review).
16. Mueller C, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptides in heart failure. Eur J Heart Fail. 2019;21(6):715-731.
17. Ponikowski P, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-1904.
18. Hundley WG, et al. ACR/ACC/AHA/SCMR/SCCT 2020 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease. J Am Coll Cardiol. 2020;75(17):2259-2290.
19. Bozkurt B, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, and the Japanese Heart Failure Society. J Card Fail. 2021;27(4):387-413.
20. Mezzani A, et al. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients. Eur J Cardiovasc Prev Rehabil. 2009;16(3):249-267.
21. Rosenkranz S, et al. Left heart heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942-954.

10. Management

The management of chronic heart failure (CHF) has evolved from a sequential "add-on" approach to a rapid, simultaneous initiation of disease-modifying therapies. The primary goals are to reduce mortality, prevent hospitalizations, and improve functional capacity and quality of life [22].

10.1 General Principles

1. Phenotype-Targeted Therapy: Management is strictly dictated by the Left Ventricular Ejection Fraction (LVEF).
2. Rapid Titration: Guidelines now emphasize reaching target doses within 4–6 weeks of diagnosis, rather than the traditional 6-month timeline [23].
3. Comorbidity Management: Addressing iron deficiency, sleep apnoea, and atrial fibrillation is integral to successful HF care.
4. Multidisciplinary Teams: HF clinics involving specialist nurses, pharmacists, and cardiologists reduce 30-day readmissions by ~30%.

10.2 Management of HFrEF (LVEF $\le$ 40%)

The "Four Pillars" of Guideline-Directed Medical Therapy (GDMT) should be initiated as soon as possible, ideally during the index hospitalization or at the first outpatient visit.

10.2.1 HFrEF Treatment Algorithm (2024–2025 Update)

       [ DIAGNOSIS OF HFrEF (LVEF ≤40%) ]
                   |
                   v
       [ THE FOUR PILLARS (Initiate ASAP) ]
       1. ARNI (preferred) or ACEi/ARB
       2. Beta-Blocker (Bisoprolol/Carvedilol/Metoprolol succ.)
       3. MRA (Spironolactone/Eplerenone)
       4. SGLT2i (Dapagliflozin/Empagliflozin)
                   |
                   v
       [ ASSESS AFTER 3-6 MONTHS OF GDMT ]
       (Repeat Echo, NYHA Class, Heart Rate)
                   |
    -------------------------------------------
    |                  |                      |
[ LVEF ≤35% ]    [ LVEF ≤35% + LBBB ]   [ HR > 70 bpm ]
[ NYHA II-III ]  [ QRS ≥130ms       ]   [ In SR      ]
    |                  |                      |
    v                  v                      v
[ ICD THERAPY ]   [ CRT-D / CRT-P ]     [ IVABRADINE ]
    |                  |                      |
    -------------------------------------------
                   |
                   v
       [ PERSISTENT SYMPTOMS / WORSENING HF ]
                   |
    -------------------------------------------
    |                  |                      |
[ Iron Defic. ]    [ Valvular HD ]     [ Advanced HF ]
[ TSAT less than 20%   ]    [ e.g. Mod-Sev MR ] [ NYHA IV     ]
    |                  |                      |
    v                  v                      v
[ IV FERRIC     ]  [ MITRACLIP / ]     [ LVAD /      ]
[ CARBOXYMALT.  ]  [ SURGERY     ]     [ TRANSPLANT  ]

10.3 Management of HFpEF (LVEF $\ge$ 50%)

Historically, HFpEF lacked proven disease-modifying therapies. The landscape changed with the SGLT2 inhibitor trials.

• SGLT2 Inhibitors (Class I): Empagliflozin (EMPEROR-Preserved) and Dapagliflozin (DELIVER) demonstrated a significant reduction in the composite of CV death and HF hospitalization [24, 25]. They are the cornerstone of HFpEF therapy.
• Diuretics (Class I): Essential for symptom relief and volume control.
• ARNI/MRA/ARB (Class IIb): May be considered, especially in patients at the lower end of the "preserved" spectrum (LVEF 50–55%).
• Comorbidity Control: Aggressive management of blood pressure (less than 130/80 mmHg), atrial fibrillation (rhythm control often preferred), and obesity.

10.4 Device Therapy Indications

10.4.1 Implantable Cardioverter Defibrillator (ICD)

• Primary Prevention: Indicated for symptomatic HF (NYHA II–III) with LVEF $\le$35% despite $\ge$3 months of optimal GDMT, provided the patient has a life expectancy > 1 year in good functional status.
  • Ischaemic: Strongest evidence (MADIT-II, SCD-HeFT).
  • Non-ischaemic: Class I recommendation remains, though DANISH trial suggested less benefit in elderly patients with non-ischaemic cardiomyopathy [26].

10.4.2 Cardiac Resynchronization Therapy (CRT)

CRT aims to restore ventricular synchrony in patients with electromechanical dyssyncrony (manifested as LBBB).

• Indications: LVEF $\le$35% despite GDMT, in sinus rhythm, with:
  • LBBB + QRS $\ge$ 150 ms: Class I (Strongest benefit).
  • LBBB + QRS 130–149 ms: Class I.
  • Non-LBBB + QRS $\ge$ 150 ms: Class IIa.
• CRT-D vs CRT-P: CRT-D (with defibrillator) is typically used unless the patient's primary limiting factor is advanced HF/comorbidities where the ICD component adds little value (CRT-P).

---

11. Pharmacology

11.1 The 'Four Pillars' of HFrEF Therapy

These agents provide an additive survival benefit. The "Triple Therapy" (ACEi+BB+MRA) reduced mortality by ~50-60%; the addition of SGLT2i adds another 15-20% relative risk reduction [27].

11.1.1 ACEi / ARB / ARNI (RAAS Inhibitors)

• Clinical Pearl: ARNI is now the preferred first-line RAAS inhibitor. If switching from an ACEi to ARNI, a 36-hour washout period is mandatory to prevent angioedema.

11.1.2 Beta-Blockers (SNS Blockade)

• Mechanism: Reverse remodeling, heart rate control, and anti-arrhythmic effects.
• Agents: Only Bisoprolol, Carvedilol, Metoprolol Succinate (ER), and Nebivolol (in elderly) are evidence-based for HF.

11.1.3 Mineralocorticoid Receptor Antagonists (MRA)

• Evidence: RALES (Spironolactone) and EMPHASIS-HF (Eplerenone) showed ~30% reduction in mortality [29].
• Monitoring: U&Es must be checked at 1 week, 4 weeks, and then 3-monthly due to risk of hyperkalaemia. Avoid if K+ > 5.0 mmol/L or eGFR less than 30 mL/min/1.73m^2.

11.1.4 SGLT2 Inhibitors

• Mechanism: Osmotic diuresis, natriuresis, improved myocardial energetics, and renoprotection.
• Evidence:
  • DAPA-HF: Dapagliflozin reduced CV death/HFH by 26% in HFrEF, regardless of diabetes status [30].
  • EMPEROR-Reduced: Empagliflozin showed a 25% reduction in primary outcome [31].
• Dosing: 10 mg OD for both agents. No titration required.

11.2 Other Pharmacotherapies

11.2.1 Ivabradine

• Mechanism: Inhibits the $I_f$ current in the sinoatrial node, slowing heart rate without affecting contractility.
• Indication: LVEF $\le$35%, Sinus Rhythm, HR $\ge$70 bpm despite maximally tolerated Beta-blockers.
• Evidence: SHIFT trial showed a reduction in HF hospitalizations.

11.2.2 Vericiguat

• Mechanism: Soluble Guanylate Cyclase (sGC) stimulator; enhances the cyclic GMP pathway, which is deficient in HF.
• Indication: "Worsening HF" (recent HF hospitalization or need for IV diuretics) despite GDMT.
• Evidence: VICTORIA trial showed a modest reduction in the composite endpoint [32].

11.2.3 Digoxin

• Indication: Primarily for rate control in AF with HF, or as a third-line agent in HFrEF to reduce hospitalizations (DIG trial). It does not improve survival.

11.2.4 Hydralazine and Isosorbide Dinitrate (H-ISDN)

• Indication: Black patients with symptomatic HFrEF despite GDMT (A-HeFT trial) or those intolerant to RAAS inhibitors.

---

12. Special Protocols

12.1 Management of Iron Deficiency

Iron deficiency (ID) is present in ~50% of HF patients and is associated with impaired exercise capacity and higher mortality, independent of anaemia.

• Screening: Check Ferritin and TSAT (Transferrin Saturation) in all HF patients.
• Definition of ID in HF: Ferritin less than 100 $\mu g/L$ OR Ferritin 100–299 $\mu g/L$ with TSAT less than 20%.
• Treatment: Intravenous Ferric Carboxymaltose (FCM). Oral iron is ineffective in HF due to poor absorption (hepcidin-mediated).
• Trials:
  • HEART-FID: Demonstrated the safety of FCM, though the impact on hard endpoints was more modest than previously thought [33].
  • IRONMAN: Suggested benefit in reducing HF hospitalizations and improving quality of life [34].

12.2 Valvular Interventions in HF

Secondary (Functional) Mitral Regurgitation (SMR) is common in HFrEF due to annular dilation and papillary muscle displacement.

• Transcatheter Edge-to-Edge Repair (TEER) / MitraClip:
  • COAPT Trial: Demonstrated that in patients with HF and 3+/4+ SMR who remained symptomatic despite maximally tolerated GDMT, MitraClip reduced mortality and HF hospitalizations by ~40-50% [35].
  • MITRA-FR: Showed no benefit, highlighting the importance of patient selection (COAPT patients had "disproportionate" MR—high MR severity relative to the degree of LV dilation).

12.3 Advanced Heart Failure

Advanced HF (Stage D) is characterized by persistent symptoms despite maximal therapy, frequent hospitalizations, and severe functional limitation.

12.3.1 Inotropes

• Agents: Milrinone (PDE3 inhibitor) or Dobutamine ($\beta_1$ agonist).
• Usage: Only as a "bridge to transplant," "bridge to LVAD," or as palliative therapy. Chronic use is associated with increased mortality due to arrhythmias.

12.3.2 Left Ventricular Assist Devices (LVAD)

• Mechanism: A continuous-flow pump (e.g., HeartMate 3) that takes blood from the LV apex and pumps it into the ascending aorta.
• Indications:
  1. Bridge to Transplant (BTT): To keep the patient alive until an organ is available.
  2. Destination Therapy (DT): For patients ineligible for transplant due to age or comorbidities.
• Outcomes: 2-year survival with modern LVADs is ~80%, comparable to transplantation [36].

12.3.3 Heart Transplantation

• Gold Standard: For eligible patients with end-stage HF.
• Eligibility: Generally age less than 70, no significant irreversible pulmonary hypertension (PVR less than 3 Wood units), and good psychosocial support.
• Survival: Median survival is ~12–15 years.

---

12.4 References (Chunk 3)

22. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032.
23. Greene SJ, et al. The Need for Speed: Rapid Titration of Guideline-Directed Medical Therapy for Heart Failure. JACC Heart Fail. 2023;11(9):1145-1157.
24. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451-1461.
25. Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER). N Engl J Med. 2022;387(12):1089-1098.
26. Køber L, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure (DANISH). N Engl J Med. 2016;375(13):1221-1230.
27. Vaduganathan M, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-128.
28. McMurray JJV, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993-1004.
29. Zannad F, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms (EMPHASIS-HF). N Engl J Med. 2011;364(1):11-21.
30. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995-2008.
31. Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413-1424.
32. Armstrong PW, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction (VICTORIA). N Engl J Med. 2020;382(20):1883-1893.
33. Mentz RJ, et al. Ferric Carboxymaltose in Heart Failure with Iron Deficiency (HEART-FID). N Engl J Med. 2023;389(11):975-986.
34. Kalra PR, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199-2209.
35. Stone GW, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure (COAPT). N Engl J Med. 2018;379(24):2307-2318.
36. Mehra MR, et al. Five-Year Outcomes in Patients with Fully Magnetically Levitated Centrifugal-Flow Left Ventricular Assist Devices (HeartMate 3). N Engl J Med. 2022;387(12):1100-1110.

13. Clinical Cases

The following cases illustrate the application of current guideline-directed medical therapy (GDMT) and advanced interventions in diverse clinical scenarios.

Case 1: De Novo HFrEF and the "Need for Speed" in GDMT

Presentation: A 52-year-old male presents with a 4-week history of progressive dyspnoea (NYHA III) and bilateral ankle swelling. He has a history of hypertension but no known CAD. Examination: BP 135/85 mmHg, HR 92 bpm (SR), JVP +4 cm, bibasilar crackles, displaced apex beat. Investigations: NT-proBNP 4,500 pg/mL. Echo shows a dilated LV with LVEF 28% and global hypokinesis. Management:

1. Inpatient Phase: Diuresis with IV Furosemide. Initiation of "low-dose" four pillars: Sacubitril/Valsartan 24/26 mg BD, Bisoprolol 1.25 mg OD, Empagliflozin 10 mg OD, and Spironolactone 25 mg OD.
2. The STRONG-HF Approach: Following the STRONG-HF trial protocol [37], the patient is seen 1 week post-discharge. Doses are up-titrated rapidly as he remains euvolemic with stable renal function (K+ 4.2, Cr 110).
3. Outcome: At 6 weeks, he is on target doses of all four pillars. Repeat Echo at 3 months shows "HF with improved EF" (HFimpEF) with LVEF 42%.

Case 2: HFpEF, Metabolic Syndrome, and the SGLT2i Breakthrough

Presentation: A 74-year-old female with Type 2 Diabetes, Obesity (BMI 34), and CKD Stage 3a presents with exertional dyspnoea (NYHA II) and bendopnoea. Examination: BP 150/90 mmHg, HR 78 bpm (AF), no peripheral oedema, but prominent JVP. Investigations: NT-proBNP 850 pg/mL (notably lower due to obesity). Echo: LVEF 58%, LA volume index 42 mL/m², E/e' ratio 16 (indicating high filling pressures), LV hypertrophy. Management:

1. Foundational Therapy: Initiated on Dapagliflozin 10 mg OD based on DELIVER and EMPEROR-Preserved data [24, 25].
2. Volume and BP Control: Chlorthalidone added for synergistic BP and volume control.
3. HFpEF Subphenotyping: Identified as the "Obesity-Diabetes" phenotype. Refered for supervised exercise training and weight management (GLP-1 receptor agonist considered) [38].
4. Outcome: Significant improvement in KCCQ (Kansas City Cardiomyopathy Questionnaire) score and reduction in NT-proBNP.

Case 3: Ischaemic Cardiomyopathy and Primary Prevention ICD

Presentation: A 65-year-old male with a history of an anterior STEMI 5 years ago (treated with PCI to LAD) presents for routine follow-up. He reports NYHA II symptoms. Investigations: ECG shows sinus rhythm with old Q-waves in V1-V4. Echo shows an apical aneurysm and LVEF 30%. He has been on optimal GDMT (ARNI, BB, MRA, SGLT2i) for 6 months. Decision Making:

1. Risk Assessment: Despite optimal medical therapy, his LVEF remains ≤35%. As his cardiomyopathy is ischaemic and he is > 40 days post-MI, he meets Class I criteria for a primary prevention ICD [22, 40].
2. Procedure: Single-chamber ICD implanted.
3. Outcome: Eight months later, he experiences a nocturnal episode of rapid VT which is successfully terminated by a single ICD shock.

Case 4: LBBB and the Dramatic Response to CRT

Presentation: A 58-year-old female with non-ischaemic dilated cardiomyopathy (NIDCM) remains symptomatic (NYHA III) despite 4 months of triple therapy (ACEi, BB, MRA). Investigations: ECG shows LBBB with a QRS duration of 165 ms. Echo: LVEF 25%, significant intraventricular dyssynchrony noted. Management:

1. Indication: Meets Class I indication for CRT-D (LVEF ≤35%, LBBB, QRS ≥150 ms) [22, 43].
2. Intervention: Cardiac Resynchronization Therapy Defibrillator (CRT-D) implanted with the LV lead placed in a lateral tributary of the coronary sinus.
3. Outcome: "Super-responder" status. At 6 months, NYHA class improved to I, and LVEF increased to 50% (reverse remodeling).

Case 5: Stage D Heart Failure and the Bridge to Transplant

Presentation: A 45-year-old male with idiopathic DCM has had four hospitalizations for decompensated HF in the last 12 months. He is currently "inotrope-dependent" (milrinone) and cannot be weaned without developing cardiogenic shock. Investigations: Peak VO₂ 10 mL/kg/min. RHC: CI 1.8 L/min/m², PAWP 28 mmHg, PVR 2.5 Wood Units. Management:

1. Evaluation: Deemed a candidate for heart transplantation. However, given the expected wait time and his size, he requires a "Bridge to Transplant" (BTT).
2. Intervention: Implantation of a HeartMate 3 LVAD [36, 45].
3. Post-Op: Successfully discharged home on anticoagulation.
4. Outcome: After 14 months of LVAD support, a compatible donor is found, and he undergoes successful orthotopic heart transplantation.

---

14. Discharge Advice

Hospital discharge represents a high-risk transition period. Patient education is the primary tool to prevent the "revolving door" of HF admissions.

14.1 Self-Monitoring and Fluid Balance

• Daily Weights: Weigh yourself every morning after using the bathroom and before breakfast.
  • Action Rule: If weight increases by > 1-1.5 kg (2-3 lbs) in 24 hours or > 2.5 kg (5 lbs) in a week, call the HF nurse immediately.
• Fluid Restriction: Generally 1.5–2.0 Litres per day. Includes water, tea, coffee, soup, and ice cream.
• Sodium Restriction: Limit to less than 2-3g of sodium per day (roughly 1 teaspoon of salt). Avoid processed foods, canned soups, and "hidden" salts in breads.

14.2 Symptom Recognition (The "Red Zone")

Patients must be taught to recognize worsening congestion early:

• Yellow Zone (Caution): Increased cough, needing more pillows to sleep (orthopnoea), increased leg swelling, decreased exercise tolerance. Action: Adjust diuretics as per pre-agreed plan.
• Red Zone (Emergency): Struggling to breathe at rest, chest pain, fainting, or weight gain that does not respond to diuretic adjustment. Action: Seek emergency care (A&E).

14.3 Medication Adherence

• The "Life-Savers": Emphasize that GDMT (the four pillars) are not for symptoms but for "staying alive and out of hospital."
• Side Effects: Explain that some medications (like Beta-blockers) may make the patient feel more tired initially, but this usually improves after 2 weeks.
• Pharmacy Coordination: Ensure a reconciled list is provided and a "blister pack" or dosette box is considered if polypharmacy is a barrier.

---

15. Pearls and Pitfalls

15.1 Clinical Pearls

• The "Normal" BNP: In obese patients, BNP levels can be 50% lower than expected. A "low-normal" BNP in a symptomatic obese patient does not exclude HF.
• The "36-Hour Rule": Never start an ARNI within 36 hours of the last ACE inhibitor dose. The risk of life-threatening angioedema is real due to dual inhibition of bradykinin degradation.
• Beta-Blocker Initiation: Never start or up-titrate a Beta-blocker in a patient who is still "wet" (clinically congested). They must be "dry" and stable first.
• SGLT2i and "Euglycaemic Ketoacidosis": Be aware that diabetic patients on SGLT2i can develop ketoacidosis with relatively normal blood glucose levels, especially during perioperative periods or severe illness.

15.2 Common Pitfalls (Pitfalls)

• The "LVEF Trap": Don't assume a patient with LVEF 55% cannot have heart failure. HFpEF is just as lethal and requires careful diagnostic workup.
• Neglecting Iron: Failing to check iron studies (Ferritin/TSAT) is a common omission. Correcting ID improves symptoms even if the patient is not anaemic.
• Overtreating the Creatinine: A 25-30% rise in creatinine after starting an ACEi/ARNI or SGLT2i is often hemodynamic and expected. Do not stop these life-saving drugs unless the rise is > 50% or K+ is > 5.5 mmol/L.
• Under-dosing: The benefit of HF medications is dose-dependent. Stopping at "starting doses" without attempting to reach "target doses" is a failure of GDMT.

---

16. Post-Operative Care

16.1 CIED Management (ICD/CRT)

• Immediate Post-Op: Monitor for lead displacement (ECG), pocket haematoma, and pneumothorax (CXR).
• Activity Restrictions: No heavy lifting or reaching above shoulder height with the ipsilateral arm for 4–6 weeks to allow lead maturation.
• Remote Monitoring: Enrollment in a remote monitoring system (e.g., Medtronic CareLink, Boston Sci Latitude) is now standard of care to detect arrhythmias and lead failures early.

16.2 LVAD Specific Care

• The "No Pulse" Phenomenon: LVADs are continuous-flow pumps. Patients often have no palpable pulse and a non-invasive BP cannot be measured with a standard cuff. BP must be measured via Doppler to find the Mean Arterial Pressure (MAP). Target MAP is 70–80 mmHg.
• The Driveline: The exit site of the cable (driveline) is the most common site of infection. Meticulous sterile dressing changes are mandatory.
• Anticoagulation: Patients must be on Warfarin (target INR 2.0–3.0) and Aspirin to prevent pump thrombosis.
• Pump Alarms: Patients and caregivers must be trained on the "Low Flow" and "Power Off" alarms. A low flow alarm often indicates dehydration (low preload) or a "suction event."

---

17. Evidence Summary: Landmark Trials

---

18. Guidelines Comparison

---

19. Appendices

19.1 NYHA Functional Classification

• Class I: No limitation of physical activity.
• Class II: Slight limitation; comfortable at rest.
• Class III: Marked limitation; less than ordinary activity causes symptoms.
• Class IV: Symptoms at rest; unable to carry out any activity.

19.2 ACC/AHA Stages of Heart Failure

• Stage A (At Risk): Patients at high risk for HF but without structural heart disease or symptoms (e.g., HTN, DM).
• Stage B (Pre-HF): Structural heart disease (e.g., low EF, LVH) but without symptoms.
• Stage C (Symptomatic HF): Structural heart disease with prior or current symptoms.
• Stage D (Advanced HF): Refractory symptoms requiring specialized interventions (LVAD, Transplant, Palliative care).

---

20. References

[1] Anderson RH, et al. Anatomy of the Heart. Hurst's The Heart, 15th Ed. 2024. [2] Katz AM. Physiology of the Heart. 6th Ed. 2021. [3] Sequeira V, van der Velden J. Historical perspective on heart function: the cardiac sarcomere. Pflugers Arch. 2017. (PMID: 28214902). [4] Granzier HL, Labeit S. The Giant Protein Titin. Circ Res. 2004. (PMID: 14764448). [5] Shiels HA, White E. The Frank-Starling Mechanism in Mammalian Heart. J Exp Biol. 2008. (PMID: 18562411). [6] GBD 2021 Heart Failure Collaborators. Global, regional, and national burden of heart failure, 1990–2021. Lancet. 2024. [7] Savarese G, et al. Global Burden of Heart Failure: A Comprehensive and Updated Review. Cardiovasc Res. 2023. (PMID: 35150240). [8] Tsao CW, et al. Heart Disease and Stroke Statistics—2024 Update. Circulation. 2024. (PMID: 38264903). [9] Mann DL. Mechanisms and Models in Heart Failure. Circulation. 1999. (PMID: 10468903). [10] Weber KT. Aldosterone in Congestive Heart Failure. N Engl J Med. 2001. (PMID: 11776266). [11] Murphy SP, et al. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020. (PMID: 32192660). [12] McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of heart failure. Eur Heart J. 2021. (PMID: 34447992). [13] Poole DC, et al. The skeletal muscle pump: reflections on its physiological roles. J Appl Physiol. 2012. (PMID: 22923508). [14] Drazner MH, et al. Prognostic Importance of Elevated Jugular Venous Pressure. N Engl J Med. 2001. (PMID: 11520447). [15] Shah SJ, et al. The S3 Gallop: Its Mechanisms and Clinical Significance. J Am Coll Cardiol. 2024. [16] Mueller C, et al. Practical guidance on the use of natriuretic peptides in heart failure. Eur J Heart Fail. 2019. (PMID: 31058443). [17] Ponikowski P, et al. Ferric carboxymaltose for iron deficiency at discharge. Lancet. 2020. (PMID: 33181079). [18] Hundley WG, et al. 2020 Appropriate Use Criteria for Multimodality Imaging. J Am Coll Cardiol. 2020. (PMID: 32204987). [19] Bozkurt B, et al. Universal Definition and Classification of Heart Failure. J Card Fail. 2021. (PMID: 33663906). [20] Mezzani A, et al. Standards for the use of cardiopulmonary exercise testing. Eur J Cardiovasc Prev Rehabil. 2009. (PMID: 19276945). [21] Rosenkranz S, et al. Left heart heart failure and pulmonary hypertension. Eur Heart J. 2016. (PMID: 26508168). [22] Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022. (PMID: 35363499). [23] Greene SJ, et al. The Need for Speed: Rapid Titration of GDMT. JACC Heart Fail. 2023. (PMID: 37389445). [24] Anker SD, et al. Empagliflozin in HFpEF (EMPEROR-Preserved). N Engl J Med. 2021. (PMID: 34449189). [25] Solomon SD, et al. Dapagliflozin in HFmrEF or HFpEF (DELIVER). N Engl J Med. 2022. (PMID: 35999288). [26] Køber L, et al. Defibrillator Implantation in Nonischemic Heart Failure (DANISH). N Engl J Med. 2016. (PMID: 27571011). [27] Vaduganathan M, et al. Estimating lifetime benefits of comprehensive therapy in HFrEF. Lancet. 2020. (PMID: 32446323). [28] McMurray JJV, et al. Angiotensin-Neprilysin Inhibition versus Enalapril (PARADIGM-HF). N Engl J Med. 2014. (PMID: 25176015). [29] Zannad F, et al. Eplerenone in Patients with Systolic Heart Failure (EMPHASIS-HF). N Engl J Med. 2011. (PMID: 21073363). [30] McMurray JJV, et al. Dapagliflozin in HFrEF (DAPA-HF). N Engl J Med. 2019. (PMID: 31535768). [31] Packer M, et al. Empagliflozin in HFrEF (EMPEROR-Reduced). N Engl J Med. 2020. (PMID: 32865375). [32] Armstrong PW, et al. Vericiguat in HFrEF (VICTORIA). N Engl J Med. 2020. (PMID: 32222134). [33] Mentz RJ, et al. Ferric Carboxymaltose in Heart Failure (HEART-FID). N Engl J Med. 2023. (PMID: 37634144). [34] Kalra PR, et al. Intravenous ferric derisomaltose in heart failure (IRONMAN). Lancet. 2022. (PMID: 36341756). [35] Stone GW, et al. Transcatheter Mitral-Valve Repair in Heart Failure (COAPT). N Engl J Med. 2018. (PMID: 30280640). [36] Mehra MR, et al. Five-Year Outcomes with HeartMate 3 (MOMENTUM 3). N Engl J Med. 2022. (PMID: 36074121). [37] Mebazaa A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF). Lancet. 2022. (PMID: 36356631). [38] Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023. (PMID: 37622681). [39] Solomon SD, et al. Sacubitril-Valsartan in Heart Failure with Preserved Ejection Fraction (PARAGON-HF). N Engl J Med. 2019. (PMID: 31475792). [40] Moss AJ, et al. Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction (MADIT-II). N Engl J Med. 2002. (PMID: 11907287). [41] Bardy GH, et al. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure (SCD-HeFT). N Engl J Med. 2005. (PMID: 15659722). [42] Bristow MR, et al. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator (COMPANION). N Engl J Med. 2004. (PMID: 15152059). [43] Cleland JGF, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure (CARE-HF). N Engl J Med. 2005. (PMID: 15753315). [44] Rose EA, et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure (REMATCH). N Engl J Med. 2001. (PMID: 11794191). [45] Mehra MR, et al. A Fully Magnetically Levitated Left Ventricular Assist Device (MOMENTUM 3). N Engl J Med. 2019. (PMID: 30883052).